Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
novel bcl2 translocation and concurrent chromosome 13q14 deletion in chronic lymphocytic leukemia a case report
Original title: “A Novel BCL2 Translocation and Concurrent Chromosome 13q14 Deletion in Chronic Lymphocytic Leukemia: A Case Report.”
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM. A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans. Ahmed pointed to the financial toxicity of indefinite continuous BTK inhibitor therapy, saying she is increasingly drawn to fixed-duration venetoclax-BTK combinations that give patients a defined treatment end point. That tension between drug cost and payment structure extends well beyond CLL, noted Cassaday, Bardin, and Huang, as expensive novel agents increasingly collide with inpatient bundled payment models. To work around this, clinicians have resorted to administering drugs in the outpatient setting under 340B pricing before same-day inpatient admission or discharging and readmitting patients specifically to access outpatient drug coverage. Huang detailed the complexity of triplet regimens, such as Bruton tyrosine kinase (BTK) inhibitors combined with venetoclax and obinutuzumab (Gazyva; Genentech) for relapsed mantle cell disease. This includes overlapping myelosuppression, TLS risk, and infection management.
Original title: “Overcoming Barriers to Precision Care and Patient Access | AJMC”
pulmonary light chain deposition disease in a patient with chronic lymphocytic leukemia
Original title: “Pulmonary Light Chain Deposition Disease in a Patient With Chronic Lymphocytic Leukemia.”
Acalabrutinib combinations approved for CLL and MCL
Original title: “NICE backs new blood cancer regimens”
studying chronic lymphocytic leukemia microenvironment in the multi omics era
Original title: “Studying Chronic Lymphocytic Leukemia Microenvironment in the Multi Omics Era.”
papillary thyroid carcinoma in a patient with long standing chronic lymphocytic leukemia a case report
Original title: “Papillary thyroid carcinoma in a patient with long-standing chronic lymphocytic leukemia: A case report.”
resolution of paraneoplastic cutaneous angioendotheliomatosis after car t cell therapy in tp53 deleted cll a case report
Original title: “Resolution of Paraneoplastic Cutaneous Angioendotheliomatosis After CAR T-Cell Therapy in TP53-Deleted CLL: A Case Report.”
Roche and Nurix Therapeutics will advance their BTK degrader for chronic lymphocytic leukemia, as well as immunology and neurology indications.
Original title: “Roche makes up to $2.3B blood cancer play with Nurix’s protein degrader”
atypical cutaneous manifestation leading to the diagnosis of chronic lymphocytic leukemia
Original title: “Atypical Cutaneous Manifestation Leading to the Diagnosis of Chronic Lymphocytic Leukemia.”
artificial intelligence enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia
Original title: “Artificial intelligence-enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia.”
progressive rapid atherosclerotic plaque formation and early stent re stenosis in an untreated cll patient a case report
Original title: “Progressive Rapid Atherosclerotic Plaque Formation and Early Stent re-Stenosis in an Untreated CLL Patient; A Case Report.”
immunogenetic architecture of chronic lymphocytic leukemia at early stage insights from the o cll1 cohort
Original title: “Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort.”
integrating venetoclax based targeted and or immune therapies for chronic lymphocytic leukemia
Original title: “Integrating venetoclax-based targeted and/or immune therapies for chronic lymphocytic leukemia.”
high risk chronic lymphocytic leukemia in a young adult treated with reduced dosage fixed duration ibrutinib and venetoclax
Original title: “High-Risk Chronic Lymphocytic Leukemia in a Young Adult Treated With Reduced-Dosage, Fixed-Duration Ibrutinib and Venetoclax.”
biology and evolution of richter transformation in chronic lymphocytic leukemia
Original title: “The biology and evolution of Richter transformation in chronic lymphocytic leukemia.”
chronic lymphocytic leukemia with igh bcl2 fusion and clonal heterogeneity phenotypic and molecular profiling analysis of a rare case
Original title: “Chronic lymphocytic leukemia with IGH/BCL2 fusion and clonal heterogeneity: phenotypic and molecular profiling analysis of a rare case.”